R. Depenbusch

发表

Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216).

C. Bokemeyer, A. Hinke, A. Stein, 2020 .

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.

A. Hinke, A. Tannapfel, T. Trarbach, 2015, The Lancet. Oncology.

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

N. Schmitz, M. Stauch, Y. Ko, 2020, Leukemia.

Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial.

A. Hinke, H. Schmoll, A. Tannapfel, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study

A. Salar, A. Lammerich, U. Martens, 2020, Supportive Care in Cancer.

Translational analysis and final efficacy of the AVETUX trial – Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer

B. Seliger, C. Bokemeyer, A. Hinke, 2022, Frontiers in Oncology.

PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer

B. Seliger, C. Bokemeyer, A. Hinke, 2021, Journal for ImmunoTherapy of Cancer.

Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma

R. Motzer, T. Powles, T. Choueiri, 2019, European journal of cancer.

Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).

C. Bokemeyer, A. Hinke, A. Stein, 2018 .

Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.

A. Hinke, A. Tannapfel, S. Al-Batran, 2018, European journal of cancer.

Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial

T. Decker, R. Depenbusch, S. Hegewisch‐Becker, 2016, Breast Cancer Research and Treatment.

Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in patients with advanced renal cell carcinoma (RCC).

T. Powles, R. Motzer, T. Choueiri, 2017 .

Quality of life in patients with metastatic colorectal cancer receiving maintenance therapy after first-line inductive treatment: A quality of life sub-analysis of the AIO KRK 0207 phase III trial

A. Hinke, H. Schmoll, A. Tannapfel, 2016 .